Thrombocytopenia differential diagnosis: Difference between revisions
No edit summary |
|||
Line 16: | Line 16: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan=" | ! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
Line 26: | Line 26: | ||
|- | |- | ||
! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
|- | |- | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
Line 90: | Line 89: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation | | align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 135: | Line 133: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + | | align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + | ||
Line 152: | Line 149: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 213: | Line 209: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |[[hemoglobinuria]] | | align="center" style="background:#F5F5F5;" + |[[hemoglobinuria]] | ||
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]] | | align="center" style="background:#F5F5F5;" + |[[Flow cytometry]] | ||
Line 245: | Line 240: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 277: | Line 271: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 287: | Line 280: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
Line 294: | Line 287: | ||
| align="center" style="background:#F5F5F5;" + |History of [[Physical trauma|trauma]], [[sepsis]], [[Cancer|malignancy]], [[vasculitis]] or [[exogenous]] [[Toxin|toxins]] | | align="center" style="background:#F5F5F5;" + |History of [[Physical trauma|trauma]], [[sepsis]], [[Cancer|malignancy]], [[vasculitis]] or [[exogenous]] [[Toxin|toxins]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 308: | Line 301: | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |Laboratory studies including [[Complete blood count|CBC]], [[Prothrombin time|PT]], [[Partial thromboplastin time|PTT]], [[Fibrin degradation product|FDP]] and [[d-dimer]] | | align="center" style="background:#F5F5F5;" + |Laboratory studies including [[Complete blood count|CBC]], [[Prothrombin time|PT]], [[Partial thromboplastin time|PTT]], [[Fibrin degradation product|FDP]] and [[d-dimer]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 342: | Line 334: | ||
* Leukocyte inclusions | * Leukocyte inclusions | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 376: | Line 367: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]] | | align="center" style="background:#F5F5F5;" + |[[Flow cytometry]] | ||
| align="center" style="background:#F5F5F5;" + |Increased | | align="center" style="background:#F5F5F5;" + |Increased | ||
Line 388: | Line 378: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 429: | Line 418: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |Small [[Platelet|platelets]] | | align="center" style="background:#F5F5F5;" + |Small [[Platelet|platelets]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 463: | Line 451: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |Normal size [[Platelet|platelets]] | | align="center" style="background:#F5F5F5;" + |Normal size [[Platelet|platelets]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 478: | Line 465: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 522: | Line 508: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl or ↑ | | align="center" style="background:#F5F5F5;" + |Nl or ↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |Laboratory findings | | align="center" style="background:#F5F5F5;" + |Laboratory findings | ||
Line 531: | Line 516: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 581: | Line 565: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
Line 613: | Line 596: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | | align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | ||
| align="center" style="background:#F5F5F5;" + |Spontaneous remission | | align="center" style="background:#F5F5F5;" + |Spontaneous remission | ||
Line 621: | Line 603: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 649: | Line 630: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 678: | Line 658: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 726: | Line 705: | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 735: | Line 713: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 763: | Line 740: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 793: | Line 769: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 819: | Line 794: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 846: | Line 820: | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]] | ! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]] | ||
! align="center" style="background:#DCDCDC;" + |[[Malaria]] | ! align="center" style="background:#DCDCDC;" + |[[Malaria]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 874: | Line 847: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |[[Babesiosis]] | ! align="center" style="background:#DCDCDC;" + |[[Babesiosis]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 926: | Line 898: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
Line 941: | Line 912: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 969: | Line 939: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 996: | Line 965: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,024: | Line 992: | ||
| align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]] | | align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]] | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,051: | Line 1,018: | ||
! align="center" style="background:#DCDCDC;" + |[[Over-the-counter drug|OTC agents]] | ! align="center" style="background:#DCDCDC;" + |[[Over-the-counter drug|OTC agents]] | ||
! align="center" style="background:#DCDCDC;" + |[[Quinine]]-containing beverages | ! align="center" style="background:#DCDCDC;" + |[[Quinine]]-containing beverages | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,097: | Line 1,063: | ||
| align="center" style="background:#F5F5F5;" + |↓↓ | | align="center" style="background:#F5F5F5;" + |↓↓ | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,108: | Line 1,073: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,160: | Line 1,124: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
Line 1,167: | Line 1,130: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma ([[Kasabach-Merritt syndrome]]) | ! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma ([[Kasabach-Merritt syndrome]]) | ||
| align="center" style="background:#F5F5F5;" + |Platelet destruction | | align="center" style="background:#F5F5F5;" + |Platelet destruction | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | + | |||
| align="center" style="background:#F5F5F5;" + | - | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | - | |||
| align="center" style="background:#F5F5F5;" + |Infants | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |- | |||
| align="center" style="background:#F5F5F5;" + |+ | |||
| align="center" style="background:#F5F5F5;" + |+ | |||
| align="center" style="background:#F5F5F5;" + |Nl | |||
| align="center" style="background:#F5F5F5;" + |- | |||
| align="center" style="background:#F5F5F5;" + |- | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |↓↓ | |||
| align="center" style="background:#F5F5F5;" + |↓ | |||
| align="center" style="background:#F5F5F5;" + |Nl | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |↑ | |||
| align="center" style="background:#F5F5F5;" + |↑ | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Kaposiform hemangioendothelioma | |||
* Tufted angioma | |||
* | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm | ! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm | ||
Line 1,197: | Line 1,162: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,228: | Line 1,192: | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,276: | Line 1,239: | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Clinical manifestation | | align="center" style="background:#F5F5F5;" + |Clinical manifestation | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,306: | Line 1,268: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Positive circulating alloantibody to a common platelet antigen | | align="center" style="background:#F5F5F5;" + |Positive circulating alloantibody to a common platelet antigen | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,336: | Line 1,297: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | | align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,370: | Line 1,330: | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |[[Proteinuria]] | | align="center" style="background:#F5F5F5;" + |[[Proteinuria]] | ||
| align="center" style="background:#F5F5F5;" + |Lab abnormalities | | align="center" style="background:#F5F5F5;" + |Lab abnormalities | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,378: | Line 1,337: | ||
! colspan="2" |Idiopathic cyclic thrombocytopenia<ref name="Go2005">{{cite journal|last1=Go|first1=Ronald S.|title=Idiopathic cyclic thrombocytopenia|journal=Blood Reviews|volume=19|issue=1|year=2005|pages=53–59|issn=0268960X|doi=10.1016/j.blre.2004.05.001}}</ref> | ! colspan="2" |Idiopathic cyclic thrombocytopenia<ref name="Go2005">{{cite journal|last1=Go|first1=Ronald S.|title=Idiopathic cyclic thrombocytopenia|journal=Blood Reviews|volume=19|issue=1|year=2005|pages=53–59|issn=0268960X|doi=10.1016/j.blre.2004.05.001}}</ref> | ||
|Unknown | |Unknown | ||
! | ! | ||
! | ! | ||
Line 1,405: | Line 1,363: | ||
|- | |- | ||
! colspan="2" |Pseudothrombocytopenia | ! colspan="2" |Pseudothrombocytopenia | ||
! | ! | ||
! | ! |
Revision as of 21:17, 23 August 2018
Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytopenia differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytopenia differential diagnosis |
Risk calculators and risk factors for Thrombocytopenia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farbod Zahedi Tajrishi, M.D.
Overview
Thrombocytopenia has a broad range of potential causes. While a good history and physical examination can be helpful to diagnose some of these causes such as drug-induced thrombocytopenia, they usually don't suffice and further evaluation is often needed. There are also some useful points that may guide the physician to an appropriate diagnosis. For example, asymptomatic, isolated thrombocytopenia most probably suggests ITP, while thrombocytopenia in critically ill, hospitalized patients is usually suggestive of iatrogenic causes (eg. dilution), platelet consumption, bone marrow suppression from infection/sepsis, or even drug-induced thrombocytopenia. One should consider however, that a wide variety of other conditions such as autoimmune disorders, nutrient deficiencies, thrombotic microangiopathies could all as well cause thrombocytopenia.
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Etiology | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | ||||||||||||||||||||||||
Lab Findings | |||||||||||||||||||||||||||
Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | UA | |||||||||||||||
Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Plt | HB | WBC | ||||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes[1] |
|
+ | - | - | -/+ | + | Elderly | Exposure to | + | Petechiae, purpura, diffuse erythematous rash | + | Nl | + | + | Shortness of breath, fatigue | ↓ | ↓ | ↓ |
|
|
Nl | Nl | Nl | Bone marrow examination + clinical manifestation |
|
Aplastic anemia | Acquired:
Inherited:
|
+ | - | - | -/+ | -/+ | Biphasic (the young and the elderly) |
Exposure to History of
|
- | - | + | Nl | - | - | Shortness of breath, fatigue, pallor | ↓ | ↓ | ↓ |
|
|
Bone marrow examination +
laboratory findings |
Inherited forms are associated with:
| |||||
Acute leukemia | + | ||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH)[2] |
|
+ | - | + | Any age
(usually younger adults) |
|
↓/Nl | ↓ | ↓/Nl |
|
Nl | Nl | hemoglobinuria | Flow cytometry | |||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | Deficiency of, or antibodies to, the metalloprotease ADAMTS13 | + | -/+ | + | Any age | + | ↓ | Fragmented RBCs | Nl | Nl |
| |||||||||||||||
Hemolytic uremic syndrome (HUS) |
|
+ | -/+ | + | Children | Nl | Nl |
| |||||||||||||||||||
DIC | + | + | - | + | Any age | History of trauma, sepsis, malignancy, vasculitis or exogenous toxins | + | + | ↓ | Schistocytes | ↑↑ | ↑ | Laboratory studies including CBC, PT, PTT, FDP and d-dimer | ||||||||||||||
Congenital platelet disorders[3][4] | MYH-9 related disorders | Cytoskeletal defects in megakaryocytes | + | - |
|
↓ |
|
||||||||||||||||||||
Bernard-Soulier syndrome | Absence of
Gp Ib-IX-V |
+ | - | - | + | - | Children | History of easy bruising and bleeding symptoms | - | - | + | Nl | - | - | - | ↓ | Nl | Nl | Large platelets | NA | Nl | Nl | Nl | Flow cytometry | Increased | ||
Gray platelet syndrome | + | - | |||||||||||||||||||||||||
Wiskott-Aldrich syndrome | Mutation in GATA-1 | + | - | Small platelets |
| ||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | 1q21.1 deletion and bone marrow failure | + | - | Normal size platelets | |||||||||||||||||||||||
Alport syndrome | + | - | |||||||||||||||||||||||||
Von Willebrand disease | VWF deficiency/dysfunction | - | - | + | Rarely | More common with O blood type | Bleeding symptoms | - | - | + | - | - | - | - | Nl/ ↓ | Nl/↓ | Nl | Large platelets | Nl | Nl or ↑ | Laboratory findings | ||||||
Nutrient deficiencies | Folate, vitamin B12, copper | + | |||||||||||||||||||||||||
Category | Condition | Etiology | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Demography | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | UA | Gold standard | Associated findings | |
Rheumatologic/autoimmune disorders | ITP |
|
+ | + | - | - | + | Any age | - | - | Ecchymoses and | + Mucocutaneous | Nl | - | - | - | ↓↓↓ | Nl | Nl | Nl | Large platelets, otherwise normal | Nl | Nl | Nl | Diagnosis of exclusion | Spontaneous remission | |
Systemic lupus erythematosus (SLE) | + | ||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | Autoantibody-mediated syndrome | + | |||||||||||||||||||||||||
Felty's syndrome | Splenomegaly | + | |||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | ↑ | ↑ | ||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | |||||||||||||||||||||||||
Tick-borne infection | + | ||||||||||||||||||||||||||
Viral infections | HIV | An ITP-like condition called primary HIV-associated thrombocytopenia | + | + | + | ||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | ||||||||||||||||||||||||||
Parasitic infections | Malaria | ||||||||||||||||||||||||||
Babesiosis | |||||||||||||||||||||||||||
Category | Condition | Etiology | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Demography | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | UA | Gold standard | Associated findings | |
Medication/toxicity | Antibiotics/ | Occurrence of drug-dependent, platelet-reactive antibodies | + | + | |||||||||||||||||||||||
Heparin-induced thrombocytopenia | Anti-heparin/PF4 antibody | + | ELISA | Early or delayed-onset | |||||||||||||||||||||||
Cytotoxic chemotherapy | + | ||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | |||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | ||||||||||||||||||||||||||
GI | Chronic liver disease | + | ↓ | + | + | ↓↓ | ↓ | ||||||||||||||||||||
Portal hypertension | |||||||||||||||||||||||||||
Category | Condition | Etiology | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Demography | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | UA | Gold standard | Associated findings | |
Vascular | Giant capillary hemangioma (Kasabach-Merritt syndrome) | Platelet destruction | - | + | - | + | - | Infants | - | + | + | Nl | - | - | ↓↓ | ↓ | Nl | ↑ | ↑ |
| |||||||
Aortic aneurysm | Platelet destruction | + | |||||||||||||||||||||||||
Cardiopulmonary bypass | Platelet destruction | - | + | - | - | + | |||||||||||||||||||||
Other | Alcohol[5] | Platelet production suppression | + | - | + | - | + | Any |
|
- | - | - | Nl | + | + | ↓ | ↓ | ↓ | Cytopenia, macrocytosis | Cytopenia, macrocytosis | ↑ | ↑ | Nl | Clinical manifestation | |||
Post-transfusion purpura[6][7] | Platelet destruction by anti-platelet antibodies | - | + | - | - | + | Women |
|
- | Purpura, petechiae | + | ↓ | - | - | - | ↓↓↓ | ↓ | Nl | Nl | NA | Nl | Nl | Nl | Positive circulating alloantibody to a common platelet antigen |
| ||
Gestational thrombocytopenia[8] | Might be physiologic adaptation of pregnancy | - | - | - | - | + | Pregnant women |
|
- | - | - | Nl | - | - | - | ↓ | Nl | Nl | Nl | NA | Nl | Nl | Nl | Diagnosis of exclusion |
| ||
HELLP syndrome[9][10] | Unknown | - | + | - | - | + | Pregnant > 25 years |
|
- | - | + | ↑ | - | + | ↓ | ↓ | Nl | NA | Nl | Nl | Proteinuria | Lab abnormalities |
| ||||
Idiopathic cyclic thrombocytopenia[11] | Unknown | ||||||||||||||||||||||||||
Pseudothrombocytopenia |
References
- ↑ Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.
- ↑ Brodsky RA (2014). "Paroxysmal nocturnal hemoglobinuria". Blood. 124 (18): 2804–11. doi:10.1182/blood-2014-02-522128. PMC 4215311. PMID 25237200.
- ↑ Nurden AT, Freson K, Seligsohn U (2012). "Inherited platelet disorders". Haemophilia. 18 Suppl 4: 154–60. doi:10.1111/j.1365-2516.2012.02856.x. PMID 22726100.
- ↑ D'Andrea G, Chetta M, Margaglione M (2009). "Inherited platelet disorders: thrombocytopenias and thrombocytopathies". Blood Transfus. 7 (4): 278–92. doi:10.2450/2009.0078-08. PMC 2782805. PMID 20011639.
- ↑ Latvala J, Parkkila S, Niemelä O (April 2004). "Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells". Alcohol. Clin. Exp. Res. 28 (4): 619–24. PMID 15100613.
- ↑ McCrae, Keith R.; Herman, Jay H. (1996). "Posttransfusion purpura: Two unusual cases and a literature review". American Journal of Hematology. 52 (3): 205–211. doi:10.1002/(SICI)1096-8652(199607)52:3<205::AID-AJH13>3.0.CO;2-E. ISSN 0361-8609.
- ↑ Pavenski, Katerina; Webert, Kathryn E.; Goldman, Mindy (2008). "Consequences of transfusion of platelet antibody: a case report and literature review". Transfusion. 48 (9): 1981–1989. doi:10.1111/j.1537-2995.2008.01796.x. ISSN 0041-1132.
- ↑ Reese, Jessica A.; Peck, Jennifer D.; Deschamps, David R.; McIntosh, Jennifer J.; Knudtson, Eric J.; Terrell, Deirdra R.; Vesely, Sara K.; George, James N. (2018). "Platelet Counts during Pregnancy". New England Journal of Medicine. 379 (1): 32–43. doi:10.1056/NEJMoa1802897. ISSN 0028-4793.
- ↑ Barnhart, Lynette (2015). "HELLP Syndrome and the Effects on the Neonate". Neonatal Network. 34 (5): 269–273. doi:10.1891/0730-0832.34.5.269. ISSN 0730-0832.
- ↑ Haram, Kjell; Svendsen, Einar; Abildgaard, Ulrich (2009). "The HELLP syndrome: Clinical issues and management. A Review". BMC Pregnancy and Childbirth. 9 (1). doi:10.1186/1471-2393-9-8. ISSN 1471-2393.
- ↑ Go, Ronald S. (2005). "Idiopathic cyclic thrombocytopenia". Blood Reviews. 19 (1): 53–59. doi:10.1016/j.blre.2004.05.001. ISSN 0268-960X.